{"generic":"Betamethasone Sodium Phosphate\/Betamethasone Acetate","drugs":["Betamethasone Sodium Phosphate\/Betamethasone Acetate","Celestone Soluspan"],"mono":{"0":{"id":"72145-s-0","title":"Generic Names","mono":"Betamethasone Sodium Phosphate\/Betamethasone Acetate"},"1":{"id":"72145-s-1","title":"Dosing and Indications","sub":{"0":{"id":"72145-s-1-4","title":"Adult Dosing","mono":"<ul><li>corticosteroid therapy should not be abruptly discontinued; dose tapering is recommended<\/li><li><b>Allergic condition:<\/b> 0.25 to 9 mg\/day IM; vary dose according to patient response<\/li><li><b>Bursitis; Adjunct:<\/b> INTRABURSAL, 0.25 to 1 mL, depending on location<\/li><li><b>Cerebral edema, associated with primary or metastatic brain tumor, craniotomy or head injury:<\/b> 0.25 to 9 mg\/day IM; vary dose depending on patient response<\/li><li><b>Complication of prematurity, Single course therapy; Prophylaxis:<\/b> 12 mg IM every 24 hours for 2 doses<\/li><li><b>Disorder of endocrine system:<\/b> 0.25 to 9 mg\/day IM; vary dose depending on patient response<\/li><li><b>Disorder of eye:<\/b> 0.25 to 9 mg\/day IM; vary dose depending on patient response<\/li><li><b>Disorder of gastrointestinal tract:<\/b> 0.25 to 9 mg\/day IM; vary dose according to patient response<\/li><li><b>Disorder of hematopoietic structure:<\/b> 0.25 to 9 mg\/day IM; vary dose according to patient response<\/li><li><b>Disorder of respiratory system:<\/b> 0.25 to 9 mg\/day IM; vary dose according to patient response<\/li><li><b>Disorder of skin:<\/b> INTRALESIONAL, 0.2 mL\/cm(2) administered intradermally; MAX 1 mL at weekly intervals<\/li><li><b>Disorder of skin:<\/b> NTRAMUSCULAR, 0.25 to 9 mg\/day; vary dose according to patient response<\/li><li><b>Exacerbation of multiple sclerosis (Acute):<\/b> 30 mg\/day IM for 1 week, followed by 12 mg IM every other day for 1 month<\/li><li><b>Gouty arthritis, acute; Adjunct:<\/b> 0.25 to 9 mg\/day IM; vary dose according to patient response<\/li><li><b>Gouty arthritis, acute; Adjunct:<\/b> 0.5 to 1 mL intra-articularly, vary dose depending on patient response<\/li><li><b>Inflammatory disorder of musculoskeletal system; Adjunct:<\/b> 0.25 to 9 mg\/day IM; vary dose depending on patient response<\/li><li><b>Leukemia, palliative management:<\/b> 0.25 to 9 mg\/day IM; vary dose depending on patient response<\/li><li><b>Malignant lymphoma, palliative management:<\/b> 0.25 to 9 mg\/day IM; vary dose depending on patient response<\/li><li><b>Multiple myeloma:<\/b> Optimal dosing and timing not yet defined<\/li><li><b>Nephrotic syndrome, idiopathic or lupus erythematosus related:<\/b> 0.25 to 9 mg\/day IM; vary dose depending on patient response<\/li><li><b>Osteoarthritis:<\/b> 0.25 to 9 mg\/day IM; vary dose according to patient response<\/li><li><b>Osteoarthritis:<\/b> 0.5 to 2.0 mL intra-articularly, vary dose depending on patient response<\/li><li><b>Primary intracranial tumor; Adjunct:<\/b> Optimal dosing and timing not yet defined<\/li><li><b>Rheumatoid arthritis; Adjunct:<\/b> 0.25 to 9 mg\/day IM; vary dose according to patient response<\/li><li><b>Rheumatoid arthritis; Adjunct:<\/b> 0.5 to 2.0 mL intra-articularly, vary dose depending on patient response<\/li><li><b>Systemic lupus erythematosus:<\/b> 0.25 to 9 mg\/day IM; vary dose according to patient response<\/li><li><b>Tenosynovitis; Adjunct:<\/b> INJECTION, 0.5 mL<\/li><li><b>Trichinosis, with neurological or myocardial involvement:<\/b> 0.25 to 9 mg\/day IM; vary dose depending on patient response<\/li><li><b>Tuberculosis of meninges; Adjunct:<\/b> 0.25 to 9 mg\/day IM; vary dose depending on patient response<\/li><\/ul>"},"1":{"id":"72145-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>corticosteroid therapy should not be abruptly discontinued; dose tapering is recommended<\/li><li><b>Allergic condition:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose according to patient response<\/li><li><b>Bursitis; Adjunct:<\/b> INTRABURSAL, 0.25 to 1 mL, depending on location<\/li><li><b>Cerebral edema, associated with primary or metastatic brain tumor, craniotomy or head injury:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose depending on patient response<\/li><li><b>Complication of prematurity, Single course therapy; Prophylaxis:<\/b> 12 mg IM every 24 hours for 2 doses<\/li><li><b>Disorder of endocrine system:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose depending on patient response<\/li><li><b>Disorder of eye:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose depending on patient response<\/li><li><b>Disorder of gastrointestinal tract:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose according to patient response<\/li><li><b>Disorder of hematopoietic structure:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose according to patient response<\/li><li><b>Disorder of respiratory system:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose according to patient response<\/li><li><b>Disorder of skin:<\/b> INTRALESIONAL, 0.2 mL\/cm(2) administered intradermally; MAX 1 mL at weekly intervals<\/li><li><b>Disorder of skin:<\/b> INTRAMUSCULAR, 0.02 to 0.3 mg\/kg\/day in three or four divided doses; vary dose according to patient response<\/li><li><b>Gouty arthritis, acute; Adjunct:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose according to patient response<\/li><li><b>Gouty arthritis, acute; Adjunct:<\/b> 0.5 to 1 mL intra-articularly, vary dose depending on patient response<\/li><li><b>Inflammatory disorder of musculoskeletal system; Adjunct:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose depending on patient response<\/li><li><b>Leukemia, palliative management:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose depending on patient response<\/li><li><b>Malignant lymphoma, palliative management:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose depending on patient response<\/li><li><b>Nephrotic syndrome, idiopathic or lupus erythematosus related:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose depending on patient response<\/li><li><b>Osteoarthritis:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose according to patient response<\/li><li><b>Osteoarthritis:<\/b> 0.5 to 2.0 mL intra-articularly, vary dose depending on patient response<\/li><li><b>Rheumatoid arthritis; Adjunct:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose according to patient response<\/li><li><b>Systemic lupus erythematosus:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose according to patient response<\/li><li><b>Tenosynovitis; Adjunct:<\/b> INJECTION, 0.5 mL<\/li><li><b>Trichinosis, with neurological or myocardial involvement:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose depending on patient response<\/li><li><b>Tuberculosis of meninges; Adjunct:<\/b> 0.02 to 0.3 mg\/kg\/day IM in three or four divided doses; vary dose depending on patient response<\/li><\/ul>"},"3":{"id":"72145-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Allergic condition<\/li><li>Bursitis; Adjunct<\/li><li>Cerebral edema, associated with primary or metastatic brain tumor, craniotomy or head injury<\/li><li>Disorder of endocrine system<\/li><li>Disorder of eye<\/li><li>Disorder of gastrointestinal tract<\/li><li>Disorder of hematopoietic structure<\/li><li>Disorder of respiratory system<\/li><li>Disorder of skin<\/li><li>Exacerbation of multiple sclerosis (Acute)<\/li><li>Gouty arthritis, acute; Adjunct<\/li><li>Inflammatory disorder of musculoskeletal system; Adjunct<\/li><li>Leukemia, palliative management<\/li><li>Malignant lymphoma, palliative management<\/li><li>Nephrotic syndrome, idiopathic or lupus erythematosus related<\/li><li>Osteoarthritis<\/li><li>Rheumatoid arthritis; Adjunct<\/li><li>Systemic lupus erythematosus<\/li><li>Tenosynovitis; Adjunct<\/li><li>Trichinosis, with neurological or myocardial involvement<\/li><li>Tuberculosis of meninges; Adjunct<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Complication of prematurity, Single course therapy; Prophylaxis<\/li><li>Disorder relating to short gestation AND\/OR low birthweight; Prophylaxis<\/li><li>Multiple myeloma<\/li><li>Primary intracranial tumor; Adjunct<\/li><\/ul>"}}},"3":{"id":"72145-s-3","title":"Contraindications\/Warnings","sub":[{"id":"72145-s-3-9","title":"Contraindications","mono":"<ul><li>administration of live or live, attenuated vaccines<\/li><li>hypersensitivity to betamethasone or any component of the product<\/li><li>IM administration for idiopathic thrombocytopenic purpura<\/li><\/ul>"},{"id":"72145-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- use with caution in patients with recent myocardial infarction due to risk of left ventricular free-wall rupture<\/li><li>-- blood pressure elevations may occur with average to large doses of corticosteroids; monitoring recommended<\/li><li>-- fluid retention or edema may occur with average to large doses of corticosteroids; use cautiously in patients with congestive heart failure, hypertension, or renal insufficiency<\/li><li>Dermatologic Effects:<\/li><li>-- Kaposi sarcoma has been reported with corticosteroid use, especially with long-term therapy; clinical improvement may occur with discontinuation<\/li><li>Endocrine Metabolic Effects:<\/li><li>-- hyperthyroidism or hypothyroidism may increase or decrease metabolic clearance of corticosteroids, respectively; dose adjustment may be required<\/li><li>-- reversible hypothalamic-pituitary-adrenal axis suppression may occur after treatment withdrawal, with potential progression to glucocorticosteroid insufficiency<\/li><li>-- increased potassium excretion or sodium retention may occur with average to large doses of corticosteroids; use cautiously in patients with congestive heart failure, hypertension, or renal insufficiency<\/li><li>Gastrointestinal Effects:<\/li><li>-- patients with diverticulitis, active or latent peptic ulcer, fresh intestinal anastomoses, or nonspecific ulcerative colitis at increased risk of gastrointestinal perforation; monitoring recommended<\/li><li>Hepatic Effects:<\/li><li>-- patients with cirrhosis may be at increased risk of toxicity<\/li><li>Immunologic Effects:<\/li><li>-- anaphylactoid reactions have rarely been reported with corticosteroid therapy<\/li><li>-- increased risk of new infection, generalized infection, or masking of preexisting infection with corticosteroid use<\/li><li>-- activation of latent disease or worsening active infection may occur (ie, viral, bacterial, fungal, protozoan, or helminthic); amebiasis screening recommended before therapy initiation in at-risk patients<\/li><li>-- exposure to chicken pox or measles during corticosteroid treatment may result in a more serious or fatal disease course, particularly in patients with no history of these infections<\/li><li>-- tuberculosis reactivation may occur; monitoring recommended<\/li><li>-- use cautiously in patients with Strongyloides (threadworm) infestation, as life-threatening enterocolitis and septicemia may develop<\/li><li>-- avoid use in patients with systemic fungal infection, unless indicated for drug reaction control<\/li><li>Musculoskeletal Effects:<\/li><li>-- risk of bone growth inhibition in pediatric patients; monitoring recommended<\/li><li>-- osteoporosis may occur, especially in postmenopausal women; monitoring recommended<\/li><li>-- intraarticular administration may damage joint tissues or cause septic arthritis; injection into joints that are unstable or with history of infection not recommended<\/li><li>Neurologic:<\/li><li>--life-threatening and fatal neurologic events (eg, stroke, cortical blindness, quadriplegia, paraplegia, spinal cord infarction) have occurred with epidural or intrathecal corticosteroid administration (off-label use), with or without fluoroscopy<\/li><li>-- avoid high doses in patients with traumatic brain injury<\/li><li>-- avoid use with cerebral malaria<\/li><li>-- increased risk of acute myopathy in patients with neuromuscular transmission disorders (eg, myasthenia gravis) or concurrent use of neuromuscular blockers (eg, pancuronium)<\/li><li>Ophthalmic Effects:<\/li><li>-- increased risk of secondary ocular infection, cataracts, and glaucoma with corticosteroid use; monitoring recommended<\/li><li>-- oral use for optic neuritis not recommended<\/li><li>-- avoid use with active ocular herpes simplex<\/li><li>-- intraocular pressure elevations may occur with long-term use (ie, longer than 6 weeks); monitoring recommended<\/li><li>Psychiatric Effects:<\/li><li>-- use may aggravate preexisting emotional instability or psychotic tendencies; monitoring recommended<\/li><li>Other:<\/li><li>-- not for IV administration<\/li><li>-- avoid use of diluents with preservatives (ie, benzyl alcohol) in premature infants and low-birthweight neonates due to risk of fatal gasping syndrome<\/li><\/ul>"},{"id":"72145-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"72145-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"72145-s-4","title":"Drug Interactions","sub":[{"id":"72145-s-4-13","title":"Contraindicated","mono":"<ul>Rotavirus Vaccine, Live (established)<\/ul>"},{"id":"72145-s-4-14","title":"Major","mono":"<ul><li>Aldesleukin (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Itraconazole (probable)<\/li><li>Pixantrone (theoretical)<\/li><\/ul>"},{"id":"72145-s-4-15","title":"Moderate","mono":"<ul><li>Alcuronium (probable)<\/li><li>Aspirin (probable)<\/li><li>Atracurium (probable)<\/li><li>Balofloxacin (established)<\/li><li>Besifloxacin (established)<\/li><li>Ciprofloxacin (established)<\/li><li>Desogestrel (probable)<\/li><li>Dienogest (probable)<\/li><li>Drospirenone (probable)<\/li><li>Enoxacin (established)<\/li><li>Estradiol Cypionate (probable)<\/li><li>Estradiol Valerate (probable)<\/li><li>Ethinyl Estradiol (probable)<\/li><li>Ethynodiol Diacetate (probable)<\/li><li>Etonogestrel (probable)<\/li><li>Fleroxacin (established)<\/li><li>Flumequine (established)<\/li><li>Fosphenytoin (probable)<\/li><li>Gallamine (probable)<\/li><li>Gatifloxacin (established)<\/li><li>Gemifloxacin (established)<\/li><li>Hexafluorenium (probable)<\/li><li>Levofloxacin (established)<\/li><li>Levonorgestrel (probable)<\/li><li>Licorice (probable)<\/li><li>Lomefloxacin (established)<\/li><li>Medroxyprogesterone Acetate (probable)<\/li><li>Mestranol (probable)<\/li><li>Metocurine (probable)<\/li><li>Moxifloxacin (established)<\/li><li>Nadifloxacin (established)<\/li><li>Norelgestromin (probable)<\/li><li>Norethindrone (probable)<\/li><li>Norfloxacin (established)<\/li><li>Norgestimate (probable)<\/li><li>Norgestrel (probable)<\/li><li>Ofloxacin (established)<\/li><li>Pazufloxacin (established)<\/li><li>Pefloxacin (established)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Primidone (probable)<\/li><li>Prulifloxacin (established)<\/li><li>Rifampin (probable)<\/li><li>Rifapentine (probable)<\/li><li>Rufloxacin (established)<\/li><li>Saiboku-To (probable)<\/li><li>Sparfloxacin (established)<\/li><li>Tosufloxacin (established)<\/li><\/ul>"}]},"5":{"id":"72145-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Acne<\/li><li><b>Endocrine metabolic:<\/b>Decreased body growth<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Acute myocardial infarction with rupture of ventricle, Cardiac arrest, Thromboembolic disorder<\/li><li><b>Endocrine metabolic:<\/b>Diabetic ketoacidosis<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis, Perforation of large intestine, Perforation of small intestine<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Musculoskeletal:<\/b>Aseptic necrosis of medial femoral condyle, Osteoporosis, Rupture of tendon<\/li><li><b>Respiratory:<\/b>Pulmonary tuberculosis<\/li><\/ul>"},"6":{"id":"72145-s-6","title":"Drug Name Info","sub":{"0":{"id":"72145-s-6-17","title":"US Trade Names","mono":"Celestone Soluspan<br\/>"},"2":{"id":"72145-s-6-19","title":"Class","mono":"<ul><li>Adrenal Glucocorticoid<\/li><li>Endocrine-Metabolic Agent<\/li><\/ul>"},"3":{"id":"72145-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"72145-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"9":{"id":"72145-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>not for IV use<br\/><\/li><li><b>Intra-articular<\/b><br\/>may be mixed with 1% or 2% lidocaine (without parabens) prior to use; do not inject lidocaine into the vial.<br\/><\/li><li><b>Intramuscular<\/b><br\/>may be mixed with 1% or 2% lidocaine (without parabens) in a syringe prior to use; do not inject lidocaine into the vial<br\/><\/li><\/ul>"},"10":{"id":"72145-s-10","title":"Monitoring","mono":"<ul><li>improvement in signs and symptoms of disease is indicative of efficacy.<\/li><li>blood pressure, height, and weight; frequently during treatment<\/li><li>development of osteoporosis; frequently during treatment<\/li><li>growth in pediatric patients<\/li><li>intraocular pressure and cataract formation; frequently during treatment, especially with prolonged use (6 weeks or longer)<\/li><\/ul>"},"11":{"id":"72145-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Injection Suspension: (Betamethasone Acetate - Betamethasone Sodium Phosphate) 3 MG\/ML-3 MG\/ML<br\/><\/li><li><b>Celestone Soluspan<\/b><br\/>Injection Suspension: (Betamethasone Acetate - Betamethasone Sodium Phosphate) 3 MG\/ML-3 MG\/ML<br\/><\/li><\/ul>"},"12":{"id":"72145-s-12","title":"Toxicology","sub":[{"id":"72145-s-12-31","title":"Clinical Effects","mono":"<b>CORTICOSTEROIDS<\/b><br\/>USES: Antiinflammatory agents used to treat a variety of clinical conditions, including adrenal insufficiency, asthma, various allergy disorders, and autoimmune disorders (eg, hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus). Corticosteroids are available in oral, parenteral, inhalational, and topical formulations. PHARMACOLOGY: Multiple mechanisms of action including anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions. Anti-inflammatory effects result from decreased formation, release and activity of the mediators of inflammation (eg, kinins, histamine, liposomal enzymes, prostaglandins, leukotrienes) which reduced the initial manifestations of the inflammatory process. The immunosuppressive properties decrease the response to delayed and immediate hypersensitivity reactions (eg, type III and type IV).  The antiproliferative effects reduce hyperplastic tissue characteristic of psoriasis. TOXICOLOGY: Corticosteroids decrease calcium absorption, increase calcium excretion, and inhibit osteoblast formation, leading to a decrease in bone formation and an increase in bone resorption, thereby contributing to the development of osteoporosis. EPIDEMIOLOGY: Acute toxicity following overdose is rare. OVERDOSE: Acute ingestion is rarely a clinical problem. Acute adrenal insufficiency rarely reported after overdose. ADVERSE EFFECTS:  Cardiac dysrhythmias (ie, atrial fibrillation)(methylPREDNISolone), seizures (methylPREDNISolone), anaphylaxis. CHRONIC EXPOSURE:  Cushingoid appearance, muscle wasting and weakness, hypertension, hyperglycemia, subcapsulary cataracts and glaucoma, osteoporosis, psychosis. ABRUPT WITHDRAWAL:  Dysphoria, irritability, emotional liability, depression, fatigue,  anxiety, depersonalization, myalgia, and arthralgia.<br\/>"},{"id":"72145-s-12-32","title":"Treatment","mono":"<b>CORTICOSTEROIDS<\/b><br\/><ul><li>Support: MANAGEMENT OF TOXICITY: Treatment is symptomatic and supportive. Seizures have been reported with IV pulse methylPREDNISolone therapy. If seizures occur, administer IV benzodiazepines, barbiturates.<\/li><li>Decontamination: PREHOSPITAL: Serious toxicity is not expected after ingestion of corticosteroids alone, and prehospital gastrointestinal decontamination is not routinely required. HOSPITAL: Significant toxicity is not expected after overdose; gastrointestinal decontamination is generally not necessary. Activated charcoal should be considered after extremely large ingestions or if more toxic coingestants are involved.<\/li><li>Airway management: Endotracheal intubation and mechanical ventilation may be required in patients with severe allergic reactions, but this is rare.<\/li><li>Antidote: None<\/li><li>Acute allergic reaction: MILD\/MODERATE: Monitor airway. Administer antihistamines with or without inhaled beta agonists, corticosteroids or epinephrine. SEVERE: Oxygen, aggressive airway management, antihistamines, epinephrine, corticosteroids, ECG monitoring and IV fluids.<\/li><li>Monitoring of patient: Routine laboratory studies are not likely to be necessary after acute overdose. Serum electrolytes and glucose are useful to assess for adverse effects from chronic therapy. Monitor vital signs, fluid and electrolyte status as indicated. Monitor neurologic status as indicated in symptomatic patients. Plasma concentrations are not readily available or clinically useful in the management of overdose.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are UNLIKELY to be of value because of the high degree of protein binding and large volume of distribution.<\/li><li>Patient disposition: HOME CRITERIA: Patients with a minor unintentional exposure who are asymptomatic or have mild symptoms can likely be managed at home. OBSERVATION CRITERIA: Moderate to severely symptomatic patients and those with deliberate overdose should be sent to a healthcare facility for evaluation and treated until symptoms resolve. ADMISSION CRITERIA: Patients who remain symptomatic despite adequate treatment should be admitted. CONSULT CRITERIA: Consult a Poison Center for assistance in managing patients with severe toxicity or in whom the diagnosis is unclear.<\/li><\/ul>"},{"id":"72145-s-12-33","title":"Range of Toxicity","mono":"<b>CORTICOSTEROIDS<\/b><br\/>TOXICITY: Acute ingestion is rarely a clinical problem; effects rarely occur with administration of less than three weeks duration.  An adolescent ingested 30 mg dexamethasone and subsequently developed acute adrenal insufficiency. Patient recovered following administration of methylPREDNISolone. CHRONIC EXPOSURE: Six infants (aged 3 to 8 months) who were treated with large amounts (up to 10 tubes for 1.5 to 5 months) of topical corticosteroids for diaper dermatitis developed Cushing's syndrome and adrenocortical insufficiency. Hepatomegaly and hepatosteatosis were observed in 5 and 3 patients, respectively. THERAPEUTIC DOSE: Varies with drug and indication.<br\/>"}]}}}